Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of the erythroid-specific enhancer region of BCL11A in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs). Methods We conducted an open-label, single-group, phase 3 study of exa-cel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β 0 /β 0 , β 0 /β 0 -like, or non–β 0 /β 0 -like genotype. CD34+ HSPCs were edited by means of CRISPR-Cas9 with a guide mRNA. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was transfusion independence, defined as a weighted average hemoglobin level of 9 g per deciliter or higher without red-cell transfusion for at least 12 consecutive months. Total and fetal hemoglobin concentrations and safety were also assessed. Results A total of 52 patients with transfusion-dependent β-thalassemia received exa-cel and were included in this prespecified interim analysis; the median follow-up was 20.4 months (range, 2.1 to 48.1). Neutrophils and platelets engrafted in each patient. Among the 35 patients with sufficient follow-up data for evaluation, transfusion independence occurred in 32 (91%; 95% confidence interval, 77 to 98; P<0.001 against the null hypothesis of a 50% response). During transfusion independence, the mean total hemoglobin level was 13.1 g per deciliter and the mean fetal hemoglobin level was 11.9 g per deciliter, and fetal hemoglobin had a pancellular distribution (≥94% of red cells). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No deaths or cancers occurred. Conclusions Treatment with exa-cel, preceded by myeloablation, resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia. (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov number, NCT03655678 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationBCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Cao, A., & Galanello, R. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd68ed · Cited by 722
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Origa, R. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.173 · Cited by 509
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309676 · Cited by 493
Self-citationTaher, A. T., Musallam, K. M., & Cappellini, M. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2021838 · Cited by 477
Self-citationResults of Long-Term Iron-Chelating Therapy
Gabutti, V., & Piga, A. (2009) · Acta Haematologica · doi:10.1159/000203853 · Cited by 378
Corbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J.-H., Dignan, F., Gibson, B., Guengoer, T., Gruhn, B., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.161 · Cited by 363
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910182 · Cited by 332
Self-citationBetibeglogene Autotemcel Gene Therapy for Non–β 0 /β 0 Genotype β-Thalassemia
Locatelli, F., Thompson, A. A., Kwiatkowski, J. L., Porter, J. B., Thrasher, A. J., Hongeng, S., Sauer, M. G., Thuret, I., Lal, A., Algeri, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2113206 · Cited by 283
Self-citationBaronciani, D., Angelucci, E., Potschger, U., Gaziev, J., Yesilipek, A., Zecca, M., Orofino, M. G., Giardini, C., Al-Ahmari, A., Marktel, S., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.293 · Cited by 241
Self-citationChallenges of blood transfusions in β-thalassemia
Shah, F. T., Sayani, F., Trompeter, S., Drasar, E., & Piga, A. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100588 · Cited by 233
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia
Musallam, K. M., Taher, A. T., Cappellini, M. D., & Sankaran, V. G. (2013) · Blood · doi:10.1182/blood-2012-10-408021 · Cited by 204
Self-citationFu, B., Liao, J., Chen, S., Li, W., Wang, Q., Hu, J., Yang, F., Hsiao, S., Jiang, Y., Wang, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01906-z · Cited by 181
Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation
Angelucci, E., Muretto, P., Lucarelli, G., Ripalti, M., BARONCIANI, D., Erer, B., GALIMBERTI, M., Giardini, C., Gaziev, J., Polchi, P., et al. (1997) · Blood · doi:10.1182/blood.v90.3.994 · Cited by 154
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Non‐transferrin‐bound iron induced by myeloablative chemotherapy
Bradley, S. J., Gosriwitana, I., Srichairatanakool, S., Hider, R. C., & Porter, J. B. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4143221.x · Cited by 112
Li, C., Mathews, V., Kim, S., George, B., Hebert, K. M., Jiang, H., Li, C., Zhu, Y., Keesler, D. A., Boelens, J. J., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000291 · Cited by 92
Arian, M., Mirmohammadkhani, M., Ghorbani, R., & Soleimani, M. (2018) · Quality of Life Research · doi:10.1007/s11136-018-1986-1 · Cited by 72
New therapeutic targets in transfusion-dependent and -independent thalassemia
Cappellini, M. D., & Motta, I. (2017) · Hematology · doi:10.1182/asheducation-2017.1.278 · Cited by 66
Self-citationParamore, C., Levine, L. M., Bagshaw, E., Ouyang, C., Kudlac, A., & Larkin, M. (2020) · Patient · doi:10.1007/s40271-020-00473-0 · Cited by 56
Changes in the quality of life of people with thalassemia major between 2001 and 2009
Costantini, M., Gollo, Savioli, et al. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s42133 · Cited by 48
Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside
Locatelli, F., Cavazzana, M., Frangoul, H., de la Fuente, J., Algeri, M., & Meisel, R. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.005 · Cited by 48
Self-citationJobanputra, M., Paramore, C., Laird, S. G., McGahan, M., & Telfer, P. T. (2020) · British Journal of Haematology · doi:10.1111/bjh.17091 · Cited by 44
Cappellini, M. D., Kattamis, A., Viprakasit, V., Sutcharitchan, P., Pariseau, J., Laadem, A., Jessent‐Ciaravino, V., & Taher, A. T. (2019) · American Journal of Hematology · doi:10.1002/ajh.25584 · Cited by 43
Self-citationSpecificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel
Yen, A., Zappala, Z., Fine, R. S., Majarian, T. D., Sripakdeevong, P., & Altshuler, D. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2313119 · Cited by 35
Chaudhury, S., Ayas, M. F., Rosen, C., Ma, M., Mohammed, V., Parikh, S. H., Kharbanda, S., Chiang, K., Haight, A. E., Bhatia, M., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.06.004 · Cited by 27
Lai, X., Liu, L., Zhang, Z., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01233-w · Cited by 22
Fogarty, W. M., Vedvick, T. S., & Itano, H. A. (1974) · British Journal of Haematology · doi:10.1111/j.1365-2141.1974.tb00496.x · Cited by 12
A systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world
Rós, F. A., Couto, S. C. F., Milhomens, J., Ovider, I., Tozatto‐Maio, K., Jennifer, V., Ramos, R. N., Picanço‐Castro, V., Kashima, S. H., Calado, R. T., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.05.006 · Cited by 10
Regulation of the β-and δ-Hemoglobin Genes
Rothschild, H., Bickers, J., & Marcus, R. (2009) · Acta Haematologica · doi:10.1159/000207949 · Cited by 7
Research works printed but not linked: 1
- Origa R. Beta-thalassemia. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews. Seattle: University of Washington, 1993.
Cited by
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309676 · Cited by 493
Self-citationPatient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
Musunuru, K., Grandinette, S. A., Wang, X., Hudson, T. R., Briseno, K., Berry, A. M., Hacker, J. L., Hsu, A., Silverstein, R. A., Hille, L. T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504747 · Cited by 368
The hidden risks of CRISPR/Cas: structural variations and genome integrity
Aussel, C., Cathomen, T., & Fuster‐García, C. (2025) · Nature Communications · doi:10.1038/s41467-025-62606-z · Cited by 89
“Forthe fi rstapprovedCRISPRtherapy, exa-cel, it is well documented that targeting the GATA1 motif in intron 2 of BCL11A suppresses gene expression in an erythroid-speci fi c manner, inducing fetal hemoglobin 58,59 .”
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
Srivastava, A., Abraham, A., Aboobacker, F. N., Singh, G., Geevar, T., Kulkarni, U. P., Selvarajan, S., Korula, A., Dave, R. G., Shankar, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2410597 · Cited by 60
“Using treosulfan instead of busulfan, as in other myeloablative conditioning protocols for HSC based gene therapy, (18, 22) we show a much-reduced toxicity profile, as is well-known in allogeneic HSC transplant for high-risk cases.”
Kwiatkowski, J. L., Walters, M. C., Hongeng, S., Yannaki, E., Kulozik, A. E., Kunz, J. B., Sauer, M. G., Thrasher, A. J., Thuret, I., Lal, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01884-1 · Cited by 56
Self-citation
Metadata
- Authors
- Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., Mapara, M., Liem, R. I., Cappellini, M. D., Algeri, M., Kattamis, A., Sheth, S., Grupp, S., Handgretinger, R., Kohli, P., Shi, D., Ross, L., Bobruff, Y., Simard, C., Zhang, L., Morrow, P. K., Hobbs, W. E., & Frangoul, H.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From IRCCS Ospedale Pediatrico Bambino Gesù (F.L., M.A.) and Catholic University of the Sacred Heart (F.L.), Rome, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.D.C.), and the Department of Health Sciences, Magna Graecia University, Catanzaro (M.A.) — all in Italy; University Children’s Hospital Tübingen (R.H.), and the Cluster of Excellence iFIT (EXC 2180) “Image-guided and Functionally Instructed Tumor Therapies” and the German Cancer Consortium, Partner Site Tübingen, University of Tübingen (P.L.), Tübingen, the Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf (R.M.), and the University of Regensburg, Regensburg (S.C.) — all in Germany; the Hospital for Sick Children and University of Toronto, Toronto (D.W.), and BC Children’s Hospital, University of British Columbia, Vancouver (A.M.L.) — all in Canada; Imperial College Healthcare NHS Trust, St. Mary’s Hospital (J.F...
- ORCID
- Locatelli, Franco
- Lang, Peter
- Wall, Donna
- Meisel, Roland
- Corbacioglu, Selim
- Li, Amanda M.
- Shah, Ami J.
- Carpenter, Ben
- Kwiatkowski, Janet L.
- Mapara, Markus
- Liem, Robert I.
- Cappellini, Maria Domenica
- Algeri, Mattia
- Kattamis, Antonis
- Sheth, Sujit
- Grupp, Stephan
- Handgretinger, Rupert
- Kohli, Puja
- Zhang, Lanju
- Morrow, Phuong Khanh
- Frangoul, Haydar
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1663-1676
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068362
- Cited by
- 253
- References
- 35
- Citations by year
- 2026: 128 · 2025: 89 · 2024: 35
- FWCI
- 70.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- CRISPR Therapeutics
- Vertex Pharmaceuticals
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, beta-thalassemia, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin, hematopoietic stem cell transplantation, myeloablative conditioning, busulfan, transfusion independence, non-viral gene therapy, autologous hematopoietic stem cells
- MeSH terms
- Gene Editing, Adolescent, Adult, Blood Transfusion, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Transplantation, Autologous, beta-Thalassemia, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.